Difference between revisions of "Melphalan (Alkeran)"
Jump to navigation
Jump to search
m (updated also known as) |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[ | + | Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[[Media:Melphalan.pdf|Melphalan (Alkeran) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, PO | <br>Route: IV, PO | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Bone cancer]] | ||
| + | *[[Hodgkin lymphoma]] | ||
| + | *[[Light-chain (AL) amyloidosis]] | ||
| + | *[[Multiple myeloma]] | ||
| + | *[[Transplant conditioning regimens]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1/17/1964: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref> | ||
==Also known as== | ==Also known as== | ||
| − | Alkerana, L-PAM, L-Phenylalanine Mustard, L-Sacrolysin, L-Sarcolysin, Levofolan, Melfalan, | + | Alkerana, L-PAM, L-Phenylalanine Mustard, L-Sacrolysin, L-Sarcolysin, Levofolan, Melfalan, Melphalan Hydrochloride. |
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Alkylating agents]] | ||
| + | [[Category:Nitrogen mustards]] | ||
| + | [[Category:Bone cancer medications]] | ||
| + | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Light-chain (AL) amyloidosis medications]] | ||
| + | [[Category:Multiple myeloma medications]] | ||
| + | [[Category:Transplant medications]] | ||
Revision as of 04:21, 16 June 2013
General information
Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bone cancer
- Hodgkin lymphoma
- Light-chain (AL) amyloidosis
- Multiple myeloma
- Transplant conditioning regimens
Patient drug information
- Melphalan (Alkeran) patient drug information (Chemocare)[3]
- Melphalan (Alkeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1/17/1964: Initial FDA approval[5]
Also known as
Alkerana, L-PAM, L-Phenylalanine Mustard, L-Sacrolysin, L-Sarcolysin, Levofolan, Melfalan, Melphalan Hydrochloride.